Markéta Žaliová

<i>IKZF1</i>^plusDefines a New Minimal Residual Disease–Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia

Martin Stanulla, Elif Dağdan, Markéta Žaliová et al. · Journal of Clinical Oncology · 2018 · 285 citations

Genomics and drug profiling of fatal TCF3-HLF−positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options

Ute Fischer, Michael Förster, Anna Maria Rinaldi et al. · Nature Genetics · 2015 · 234 citations · Full text

Therapeutic Options, Tumor Biology, Hematological Malignancy +8

IKZF1 status as a prognostic feature in BCR-ABL1–positive childhood ALL

Arian van der Veer, Markéta Žaliová, Federica Mottadelli et al. · Blood · 2013 · 148 citations

Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology

Lenka Hovorková, Markéta Žaliová, Nicola C. Venn et al. · Blood · 2017 · 128 citations · Full text

Genomic landscape of pediatric B-other acute lymphoblastic leukemia in a consecutive European cohort

Markéta Žaliová, Jan Stuchlý, Lucie Winkowska et al. · Haematologica · 2019 · 113 citations · Full text